These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 17152683)
1. A risk score for predicting death in Chagas' heart disease. Viotti R; Vigliano C; Armenti A N Engl J Med; 2006 Dec; 355(23):2489; author reply 2490-1. PubMed ID: 17152683 [No Abstract] [Full Text] [Related]
2. Case 2-2010: a man with abdominal and flank pain. Rassi A; Rassi A N Engl J Med; 2010 May; 362(20):1943-4; author reply 1944-5. PubMed ID: 20484406 [No Abstract] [Full Text] [Related]
3. Treating patients with Chagas' cardiomyopathy with chronic heart failure in the contemporary era. Bestetti RB; Theodoropoulos TA; Cardinalli-Neto A Am Heart J; 2007 Nov; 154(5):e35; author reply e33. PubMed ID: 17967576 [No Abstract] [Full Text] [Related]
4. Development and validation of a risk score for predicting death in Chagas' heart disease. Rassi A; Rassi A; Little WC; Xavier SS; Rassi SG; Rassi AG; Rassi GG; Hasslocher-Moreno A; Sousa AS; Scanavacca MI N Engl J Med; 2006 Aug; 355(8):799-808. PubMed ID: 16928995 [TBL] [Abstract][Full Text] [Related]
5. A risk score for predicting death in Chagas' heart disease. Kamath SA; Drazner MH N Engl J Med; 2006 Dec; 355(23):2489; author reply 2490-1. PubMed ID: 17162762 [No Abstract] [Full Text] [Related]
6. Beta-adrenergic blockers in chronic systolic heart failure secondary to Chagas' disease. Dávila DF; Donis JH; Torres A; Gottberg CF; Ramoni-Perazzi P; Arata de Bellabarba G Int J Cardiol; 2008 Aug; 128(1):1-4. PubMed ID: 18378338 [No Abstract] [Full Text] [Related]
7. Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy. Theodoropoulos TA; Bestetti RB; Otaviano AP; Cordeiro JA; Rodrigues VC; Silva AC Int J Cardiol; 2008 Aug; 128(1):22-9. PubMed ID: 18258318 [TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic systolic heart failure secondary to Chagas heart disease in the current era of heart failure therapy. Bestetti RB; Theodoropoulos TA; Cardinalli-Neto A; Cury PM Am Heart J; 2008 Sep; 156(3):422-30. PubMed ID: 18760121 [TBL] [Abstract][Full Text] [Related]
9. [Atrial fibrillation in patients with heart failure. Pathophysiological concepts and therapeutic options]. Boldt LH; Rolf S; Dietz R; Haverkamp W Dtsch Med Wochenschr; 2008 Nov; 133(45):2349-54. PubMed ID: 18958832 [No Abstract] [Full Text] [Related]
10. [Therapeutic aims for atrial fibrillation in patients with heart failure]. Lewalter T; Nitschmann S Internist (Berl); 2009 Jan; 50(1):101-3. PubMed ID: 19137270 [No Abstract] [Full Text] [Related]
11. A risk score for predicting death in Chagas' heart disease. Focosi D N Engl J Med; 2006 Dec; 355(23):2489-90; author reply 2490-1. PubMed ID: 17162761 [No Abstract] [Full Text] [Related]
12. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators. Pietrasik G; Goldenberg I; McNitt S; Polonsky B; Moss AJ; Zareba W J Cardiovasc Electrophysiol; 2009 Apr; 20(4):395-400. PubMed ID: 19017351 [TBL] [Abstract][Full Text] [Related]
13. Letter by Rassi et al regarding article, "Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial". Rassi A; Rassi A Circ Heart Fail; 2010 May; 3(3):e11; author reply e15. PubMed ID: 20484185 [No Abstract] [Full Text] [Related]
14. Implantable cardioverter defibrillator therapy for patients with chronic Chagas' disease: a randomized trial may not be necessary in high-risk patients. Bestetti R; Cardinalli-Neto A Europace; 2009 Apr; 11(4):537. PubMed ID: 19279026 [No Abstract] [Full Text] [Related]
15. Prognostic factors affecting the all-cause death and sudden cardiac death rates of post myocardial infarction patients with low left ventricular ejection fraction. Dai SM; Zhang S; Chen KP; Hua W; Wang FZ; Chen X Chin Med J (Engl); 2009 Apr; 122(7):802-6. PubMed ID: 19493393 [TBL] [Abstract][Full Text] [Related]
16. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Marin-Neto JA; Rassi A; Morillo CA; Avezum A; Connolly SJ; Sosa-Estani S; Rosas F; Yusuf S; Am Heart J; 2008 Jul; 156(1):37-43. PubMed ID: 18585495 [TBL] [Abstract][Full Text] [Related]